

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1-69. (Cancelled)

70. (Previously Presented) An antibody that binds human IL-13, wherein said antibody binds to an epitope comprising the sequence ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO:19).

71. (Previously Presented) The antibody of claim 70, wherein the antibody comprises CDRH1, CDRH2 and CDRH3 with the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively.

72. (Previously Presented) The antibody of claim 70, wherein the antibody comprises CDRL1, CDRL2 and CDRL3 with the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

73. (Previously Presented) The antibody of claim 71, wherein the antibody comprises CDRL1, CDRL2 and CDRL3 with the sequences of SEQ ID NO: 99, SEQ ID NO: 104 and SEQ ID NO: 115, respectively.

74. (Currently Amended) The antibody of claim 70, wherein said antibody comprises ~~a heavy chain comprising:~~

- (1) a CDRH1 having the amino acid sequence SEQ ID NO: 117, 118, 119, 120, 121 or 122;
- (2) a CDRH2 having the amino acid sequence SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and
- (3) a CDRH3 having the amino acid sequence SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.

75. (Currently Amended) The antibody of claim 70, wherein said antibody comprises a ~~heavy chain comprising a VH chain with at least 85% identity to~~ the amino acid sequence of SEQ ID NO: 143, 145, 146, 147, 148 or 149.

76. (Cancelled)

77. (Currently Amended) The antibody of claim 70, wherein said antibody comprises a ~~light chain comprising:~~

(1) a CDRL1 having the amino acid sequence SEQ ID NO: 99, 100, 101, 102, or 103;

(2) a CDRL2 having the amino acid sequence SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and

(3) a CDRL3 having the amino acid sequence SEQ ID NO: 115 or 116.

78. (Currently Amended) The antibody of claim 70, wherein said antibody comprises a ~~light chain comprising a VL chain with at least 85% identity to~~ the amino acid sequence of SEQ ID NO: 142, 144 or 150.

79. (Canceled)

80. (Currently Amended) The antibody of claim 70, wherein said antibody comprises a ~~VL light chain with one of the following~~ comprising the amino acid sequences of SEQ ID NO: 142, 144 or 150; and said antibody comprises a ~~VH heavy chain with one of the following~~ comprising the amino acid sequences of SEQ ID NO: 143, 145, 146, 147, 148 or 149.

81. (Previously Presented) The antibody of any one of claims 70 to 73, wherein the antibody is an IgG antibody.

82. (Previously Presented) The antibody of claim 81, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

83. (Previously Presented) The antibody of any one of claims 70 to 73, wherein the antibody is humanized.

84. (Previously Presented) The antibody of any one of claims 70 to 73, wherein the antibody is an antibody fragment.
85. (Previously Presented) The antibody of any one of claims 70 to 73, wherein the antibody is a single chain antibody or a single domain antibody.
86. (Previously Presented) A method for treating asthma in a patient, comprising administering to a patient in need thereof an effective amount of the antibody of any one of claims 70 to 80.
87. (Previously Presented) A method for treating an inflammatory disease in a patient, comprising administering to a patient in need thereof an effective amount of the antibody of any one of claims 70 to 80.
88. (Previously Presented) The method of claim 86, wherein the antibody is humanized.
89. (Previously Presented) The method of claim 87, wherein the antibody is humanized.
90. (Previously Presented) The method of claim 86, wherein the effective amount is between 0.1mg/kg and 20/mg/kg.
91. (Previously Presented) The method of claim 87, wherein the effective amount is between 0.1mg/kg and 20/mg/kg.
92. (Previously Presented) A pharmaceutical composition comprising the antibody of any one of claims 70 to 80.
93. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 83.
94. (New) The antibody of claim 70, wherein said antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 142, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 143.
95. (New) A hybridoma cell line that produces the antibody of claim 70 or 73.

96. (New) A DNA sequence encoding a heavy chain of an antibody or a fragment thereof that binds human IL-13, wherein said antibody binds to an epitope comprising the sequence ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO:19).
97. (New) A DNA sequence encoding a light chain of an antibody or a fragment thereof that binds human IL-13, wherein said antibody binds to an epitope comprising the sequence ESLINVSG (SEQ ID NO: 18) or YCAALESLINVS (SEQ ID NO:19).
98. (New) The DNA sequence of claim 96 which encodes a heavy chain or a fragment thereof comprising CDRH1, CDRH2 and CDRH3 with the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively.
99. (New) The DNA sequence of claim 97 which encodes a light chain or a fragment thereof comprising CDRL1, CDRL2 and CDRL3 with the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.
100. (New) The DNA sequence of claim 96 which encodes a heavy chain or a fragment thereof comprising the amino acid sequence of SEQ ID NO: 143.
101. (New) The DNA sequence of claim 97 which encodes a light chain or a fragment thereof comprising the amino acid sequence of SEQ ID NO: 142.
102. (New) The DNA sequence of claim 96 which encodes a heavy chain or a fragment thereof comprising:
- (1) a CDRH1 having the amino acid sequence of SEQ ID NO: 117, 118, 119, 120, 121 or 122;
  - (2) a CDRH2 having the amino acid sequence of SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and
  - (3) a CDRH3 having the amino acid sequence of SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.
103. (New) The DNA sequence of claim 97 which encodes a light chain or a fragment thereof comprising:

- (1) a CDRL1 having the amino acid sequence of SEQ ID NO: 99, 100, 101, 102, or 103;
- (2) a CDRL2 having the amino acid sequence of SEQ ID NO: 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and
- (3) a CDRL3 having the amino acid sequence of SEQ ID NO: 115 or 116.

104. (New) The DNA sequence of claim 96 which encodes a heavy chain or a fragment thereof comprising the amino acid sequence of SEQ ID NO: 4, 143, 145, 146, 147, 148 or 149.

105. (New) The DNA sequence of claim 97 which encodes a light chain or a fragment thereof comprising the amino acid sequence of SEQ ID NO: 3, 142, 144 or 150.

106. (New) The DNA sequence of claim 98 which encodes a heavy chain or a fragment thereof of a humanized antibody, an antibody fragment, a single chain antibody, or a single domain antibody.

107. (New) The DNA sequence of claim 99 which encodes a light chain or a fragment thereof of a humanized antibody, an antibody fragment, a single chain antibody, or a single domain antibody.

108. (New) A vector comprising the DNA sequence of claim 96 or 97.

109. (New) A host cell comprising the vector of claim 108.